event:
Hubei Provincial Medical Security Bureau issued the publicity of the proposed winning results of centralized procurement of Chinese patent medicines by inter provincial alliance, which publicized the proposed winning results of centralized procurement of Chinese patent medicines in 19 provinces and regions.
comment:
The bid winning price of this centralized purchase has decreased by 42% on average, and the price reduction range is relatively mild. On December 21, at the centralized procurement information disclosure conference of Chinese patent medicine alliance held in Hubei, 157 enterprises and 182 products from 17 product groups in the procurement catalogue participated. Through on-site competition, 97 enterprises and 111 products were selected, with a selection rate of 62%. The dosage forms and specifications of the selected products are complete; The winning price decreased by 42% on average and 82% at the maximum. In terms of listed companies, Beijing Beijing Tongrentang Co.Ltd(600085) Huoxue Zhitong powder reduced prices by 19% and Xiaojin pill by 20%; Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) Yixinshu tablets reduced by 40%; Hangzhou Zhejiang Conba Pharmaceutical Co.Ltd(600572) Ginkgo biloba capsule reduced its price by 29%; Huadong Medicine Co.Ltd(000963) bailing capsule reduces the price by 57%; Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) the price of Shuxuening injection decreased by 41%; Jianmin Pharmaceutical Group Co.Ltd(600976) the price of Ginkgo biloba leaves is reduced by 35%, and that of Xiaojin capsule is reduced by 36%; Jilin Aodong Pharmaceutical Group Co.Ltd(000623) Xuefu Zhuyu oral liquid reduces the price by 3%; Kpc Pharmaceuticals Inc(600422) the price of Xuesaitong for injection (freeze-drying) is reduced by 54%, and that of Xuesaitong dropping pills is reduced by 36%; Sichuan Kelun Pharmaceutical Co.Ltd(002422) the price of Ginkgo leaves is reduced by 27%.
There are many provinces involved in this centralized mining, covering a wide range of varieties. The inter provincial alliance is composed of 19 provinces including Hubei, Hebei, Shanxi, Inner Mongolia, Liaoning, Fujian, Jiangxi, Henan, Hunan, Hainan, Chongqing, Sichuan, Guizhou, Tibet, Shaanxi, Gansu, Ningxia, Xinjiang and Xinjiang production and Construction Corps. It aims to expand the coverage of centralized and institutionalized drug procurement, guide the price of Chinese patent medicine to return to a reasonable level, and effectively reduce the medical burden of the people. The selected products also cover the recommended drugs of covid-19 pneumonia diagnosis and treatment scheme in the eighth edition of some countries. At present, most of the mainstream products used clinically and the recommended drugs of covid-19 pneumonia diagnosis and treatment plan are selected, which can effectively meet the drug needs of clinical and normalized epidemic prevention and control. According to the calculation of the annual demand of the 19 provincial alliance, it is estimated that the annual drug cost can be saved by more than 2.6 billion yuan. The price reduction effect of centralized purchase of Chinese patent medicine alliance will radiate to the whole country, and the drug cost burden of patients is expected to be further reduced, contributing to the normalization of epidemic prevention and control.
This centralized purchase mainly has four characteristics. First, establish an inter provincial alliance to collect mainstream proprietary Chinese medicine varieties with large clinical use and high purchase amount; Second, the comprehensive evaluation competition is based on the price decline, supplemented by clinical recognition, production and supply capacity, innovation ability, drug quality, bidding and procurement credit rating, which has explored a new path for the continuous centralized procurement of Chinese patent medicines; Third, the participation of medical institutions is high, with more than 24000 medical institutions in the alliance provinces participating in the reporting volume; Fourth, taking the opportunity of centralized procurement of Chinese patent medicine, the bidding and procurement subsystem of Hubei Medical insurance service platform has become the first provincial bidding and procurement subsystem in China.
Investment strategy. The price reduction range of this centralized purchase is relatively mild. Group A of this centralized purchase did not experience an extreme decrease of up to 90%. The price of most drugs decreased by 30% – 50%, and that of some drugs decreased by only 10% – 30%. In addition, the policy side of the traditional Chinese medicine industry is relatively friendly, and the valuation of most targets in the industry is low. It is recommended to focus on Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) (600436), Yunnan Baiyao Group Co.Ltd(000538) (000538), Beijing Tongrentang Co.Ltd(600085) (600085), Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) (600332), China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) (000999), Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) (002603), Tasly Pharmaceutical Group Co.Ltd(600535) (600535) with brand value and exclusive product advantages.
Risk statement The implementation progress of traditional Chinese medicine support policies was lower than expected, and the covid-19 epidemic affected the terminal sales of OTC varieties of traditional Chinese medicine.
